KR101190791B1 - 베타-알라닌의 지속적 방출을 위한 조성물 및 방법 - Google Patents

베타-알라닌의 지속적 방출을 위한 조성물 및 방법 Download PDF

Info

Publication number
KR101190791B1
KR101190791B1 KR1020077030038A KR20077030038A KR101190791B1 KR 101190791 B1 KR101190791 B1 KR 101190791B1 KR 1020077030038 A KR1020077030038 A KR 1020077030038A KR 20077030038 A KR20077030038 A KR 20077030038A KR 101190791 B1 KR101190791 B1 KR 101190791B1
Authority
KR
South Korea
Prior art keywords
alanine
beta
enol
delete delete
free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077030038A
Other languages
English (en)
Korean (ko)
Other versions
KR20080028374A (ko
Inventor
로저 해리스
존 와이즈
Original Assignee
내츄럴 얼터너티브즈 인터내셔날, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 내츄럴 얼터너티브즈 인터내셔날, 인크. filed Critical 내츄럴 얼터너티브즈 인터내셔날, 인크.
Publication of KR20080028374A publication Critical patent/KR20080028374A/ko
Application granted granted Critical
Publication of KR101190791B1 publication Critical patent/KR101190791B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020077030038A 2005-05-23 2006-05-23 베타-알라닌의 지속적 방출을 위한 조성물 및 방법 Expired - Lifetime KR101190791B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68398505P 2005-05-23 2005-05-23
US60/683,985 2005-05-23
PCT/US2006/020104 WO2007073398A2 (en) 2005-05-23 2006-05-23 Compositions and methods for the sustained release of beta-alanine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020127017805A Division KR101275660B1 (ko) 2005-05-23 2006-05-23 베타-알라닌의 지속적 방출을 위한 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20080028374A KR20080028374A (ko) 2008-03-31
KR101190791B1 true KR101190791B1 (ko) 2012-10-12

Family

ID=38189110

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077030038A Expired - Lifetime KR101190791B1 (ko) 2005-05-23 2006-05-23 베타-알라닌의 지속적 방출을 위한 조성물 및 방법
KR1020127017805A Expired - Lifetime KR101275660B1 (ko) 2005-05-23 2006-05-23 베타-알라닌의 지속적 방출을 위한 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127017805A Expired - Lifetime KR101275660B1 (ko) 2005-05-23 2006-05-23 베타-알라닌의 지속적 방출을 위한 조성물 및 방법

Country Status (8)

Country Link
US (8) US8329207B2 (OSRAM)
EP (2) EP1883406B1 (OSRAM)
JP (2) JP5336180B2 (OSRAM)
KR (2) KR101190791B1 (OSRAM)
CN (2) CN101309688B (OSRAM)
CA (1) CA2621365C (OSRAM)
DK (2) DK3081215T3 (OSRAM)
WO (1) WO2007073398A2 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504376B2 (en) 1996-08-12 2009-03-17 Natural Alternatives International Methods and compositions for increasing the anaerobic working capacity in tissues
US5965596A (en) 1997-08-12 1999-10-12 Harris; Roger Methods and compositions for increasing the anaerobic working capacity in tissue
CA2621365C (en) 2005-05-23 2012-09-04 Natural Alternatives International Compositions and methods for the sustained release of beta-alanine
US7956218B2 (en) * 2007-12-12 2011-06-07 Northern Innovations And Formulations Corp. Organic salts of β-alanine
AU2007362357A1 (en) * 2007-12-12 2009-06-18 Northern Innovations And Formulations Corp. Organic salts of beta-alanine
JP5519945B2 (ja) * 2009-03-10 2014-06-11 株式会社ファンケル 抗不安剤
US20120010291A1 (en) * 2009-08-12 2012-01-12 Kneller Bruce W CREATINE Beta-ALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE
US9414615B2 (en) * 2010-01-18 2016-08-16 PepciCo, Inc. Gel-based compositions and methods of making same
TW201201713A (en) * 2010-04-05 2012-01-16 Abbott Lab Shelf stable nutritional liquids comprising beta alanine
TW201320908A (zh) * 2011-10-13 2013-06-01 Abbott Lab 包含β－丙胺酸之營養產品
CN104023557A (zh) * 2012-01-03 2014-09-03 雀巢产品技术援助有限公司 用于食物基质中反应性氨基酸的稳定性的组合物和方法
US8496979B1 (en) * 2012-02-02 2013-07-30 Reliv International, Inc. Caffeine-free dietary supplements for increasing energy and methods of administering the same
EP2666365A1 (en) * 2012-05-22 2013-11-27 Taminco Treatment of poultry, pigs or fish for reducing the feed conversion ratio.
ITMI20121586A1 (it) * 2012-09-24 2014-03-25 N G C Medical Spa L-carnosina per il trattamento delle miopatia congenita mitocondriale e della sindrome della fatica muscolare cronica
CN103005435B (zh) * 2012-12-13 2014-01-29 北京康比特体育科技股份有限公司 一种抗疲劳、提高速度耐力的组合物及含其制剂
WO2014117176A1 (en) 2013-01-28 2014-07-31 Lopez Hector L Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor
EP3035809A4 (en) * 2013-08-20 2017-03-08 Natural Alternatives International, Inc. Method of maintaining or improving tactical performance through dietary supplementation
WO2016138454A1 (en) * 2015-02-27 2016-09-01 Natural Alternatives International, Inc. Methods of improving physiological responses related to post-traumatic stress disorder through dietary supplementation
WO2017053171A1 (en) * 2015-09-25 2017-03-30 Natural Alternatives International, Inc. Methods of improving physiological conditions related to pregnancy and development of offspring through dietary supplementation
CN105663081B (zh) * 2015-12-30 2019-08-02 大连医诺生物股份有限公司 微囊化β-丙氨酸
WO2017142542A1 (en) * 2016-02-19 2017-08-24 Hewlett Packard Enterprise Development Lp Linear transformation accelerators
WO2018226987A1 (en) * 2017-06-07 2018-12-13 The Regents Of The University Of California Compositions for treating fungal and bacterial biofilms and methods of using the same
WO2020117755A1 (en) 2018-12-03 2020-06-11 The Regents Of The University Of California Compositions and methods for treating biofilms
CN114302718A (zh) * 2019-06-28 2022-04-08 有机合成药品工业株式会社 线粒体功能活化剂
JP6749665B1 (ja) * 2019-07-18 2020-09-02 株式会社東洋新薬 経口組成物
WO2021041662A1 (en) * 2019-08-29 2021-03-04 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peripheral nerve agonists suppress inflammation
WO2021236440A1 (en) 2020-05-20 2021-11-25 Advanced Food Concepts, Inc. Athletic performance enhancement composition using menthol
CN111956780A (zh) * 2020-08-28 2020-11-20 黑龙江现代物联网科技有限公司 一种用鹅肌肽制成降低人体尿酸的饮用水及其制备方法
CN113812635B (zh) * 2021-09-22 2023-12-19 大连医诺生物股份有限公司 微囊化β-丙氨酸、其制备方法及应用
WO2026017801A1 (de) 2024-07-17 2026-01-22 Hahn Carsten Mittel zur aufbringung auf hautpartien eines menschen zur leistungssteigerung von unter den hautpartien angeordneter muskeln des menschen bei anaerober belastung

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966988A (en) 1971-07-28 1976-06-29 International Flavors & Fragrances Inc. Flavoring compositions and processes utilizing dithiazine compounds
USRE30370E (en) 1971-11-04 1980-08-12 International Flavors & Fragrances Inc. Flavoring foodstuffs with a thioester
DE2519656A1 (de) 1974-05-13 1975-11-27 Sandoz Ag Neue peptide und verfahren zu ihrer herstellung
US3934036A (en) 1975-01-23 1976-01-20 Kyorin Seiyaku Kabushiki Kaisha N-benzenesulfonyl-β-alanine hydrazide useful as an immunosuppressive agent
JPS54159393A (en) 1978-06-08 1979-12-17 Ajinomoto Co Inc Polyamino acid-coated activated carbon
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS6016934A (ja) 1983-07-06 1985-01-28 Kaneshiro Nagai 抗腫瘍剤
IT1176983B (it) 1984-10-16 1987-08-26 Zambon Spa Dipeptidi ad attivita' farmacologica
JPS61204120A (ja) 1985-03-07 1986-09-10 Kaneshiro Nagai 免疫調節剤
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
DE3613758A1 (de) 1986-04-23 1987-10-29 Consortium Elektrochem Ind Cysteinreiche, (gamma)-glutaminsaeure- und (beta)-alanin-einheiten aufweisende peptide, verfahren zu deren herstellung und ihre verwendung
FR2609893B1 (fr) 1987-01-26 1990-03-30 Rougereau Andre Composition a base d'acides amines et de vitamines utilisable en therapeutique cancerologique
JPS6442425A (en) 1987-08-11 1989-02-14 Nippon Univ Remedy for cachexia
WO1990006102A1 (en) 1988-09-28 1990-06-14 Peptide Technology Limited Compound and method for the retardation of collagen cross-linking
JPH0395125A (ja) 1989-05-23 1991-04-19 Otsuka Pharmaceut Co Ltd カルシウム代謝改善剤
IT1240336B (it) 1990-03-21 1993-12-07 Setra Composizioni farmaceutiche,dietetiche o veterinarie ad attivita' eumetabolica
JP2873493B2 (ja) 1990-08-09 1999-03-24 理化学研究所 血糖調節剤
JP2873497B2 (ja) 1990-09-03 1999-03-24 理化学研究所 脂質代謝調節剤
US5190775A (en) 1991-05-29 1993-03-02 Balchem Corporation Encapsulated bioactive substances
JPH07500580A (ja) 1991-09-09 1995-01-19 ペプテック　リミテッド 糖尿病の合併症及び病因の処理方法
JPH0624976A (ja) 1992-07-10 1994-02-01 Rikagaku Kenkyusho 輸液用組成物
GB9215746D0 (en) 1992-07-24 1992-09-09 Hultman Eric A method of increasing creatine supply depot
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
JP3213666B2 (ja) 1994-02-28 2001-10-02 治彦 末岡 クレアチン飲料の製造方法
DE69529043T2 (de) 1994-09-30 2003-05-08 L'oreal S.A., Paris Verwendung von einem Agonisten eines mit einem Chloridkanal assozierten Rezeptors zur Behandlung von Hautfalten
JP3595373B2 (ja) 1995-02-20 2004-12-02 治彦 末岡 クレアチン飲料
IT1275434B (it) 1995-05-19 1997-08-07 Farmila Farma Milano Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
WO1997026893A1 (en) 1996-01-24 1997-07-31 Aliatros Medical, A.S. Composition for treating cancer containing a ribose compound, beta-alanine, ascorbic acid and nicotinic acid
US6274161B1 (en) 1996-05-31 2001-08-14 The Howard Foundation Compositions containing creatine in suspension
GB9611356D0 (en) * 1996-05-31 1996-08-07 Howard Alan N Improvements in or relating to compositions containing Creatine, and other ergogenic compounds
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
AU4029397A (en) * 1996-08-12 1998-03-06 Mark Dunnett Methods and compositions for increasing the anaerobic working capacity in tissues
US7504376B2 (en) 1996-08-12 2009-03-17 Natural Alternatives International Methods and compositions for increasing the anaerobic working capacity in tissues
US5965596A (en) * 1997-08-12 1999-10-12 Harris; Roger Methods and compositions for increasing the anaerobic working capacity in tissue
KR20010012374A (ko) * 1997-05-16 2001-02-15 스티븐 엠. 오드레 지속 효과를 갖는 서방성 겔
US6019999A (en) * 1997-12-03 2000-02-01 Miller; David F. Process for making liposomal ion-exchange whey protein and products thereof
AU742250B2 (en) 1997-12-26 2001-12-20 Astellas Pharma Inc. Sustained release medicinal compositions
US20010041187A1 (en) * 1998-10-20 2001-11-15 Carl W Hastings Performance-enhancing dietary supplement
GB9924650D0 (en) * 1999-10-19 1999-12-22 Marathade Ltd Energy bar
WO2003024427A1 (en) * 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
ATE309822T1 (de) 2000-04-19 2005-12-15 Genentech Inc Formulierungen mit verzögerter freisetzung enthaltend wachstumshormon
JP2002051730A (ja) 2000-08-08 2002-02-19 Nippon Meat Packers Inc スポーツ用食品
US6855727B2 (en) 2000-12-04 2005-02-15 Yaizu Suisankagaku Industry Co., Ltd. Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect
WO2002056863A2 (en) 2000-12-29 2002-07-25 Bausch & Lomb Incorporated Sustained release drug delivery devices
MXPA03007757A (es) 2001-03-02 2004-03-16 Howard Foundation Composiciones que contienen creatina y creatinina.
AU2003234146A1 (en) * 2002-04-22 2003-11-03 Experimental And Applied Sciences, Inc. Food supplements containing 4-hydroxyisoleucine and creatine
US6835397B2 (en) * 2002-12-23 2004-12-28 Balchem Corporation Controlled release encapsulated bioactive substances
CA2621365C (en) 2005-05-23 2012-09-04 Natural Alternatives International Compositions and methods for the sustained release of beta-alanine

Also Published As

Publication number Publication date
EP1883406A4 (en) 2009-11-04
JP5336180B2 (ja) 2013-11-06
US9907769B2 (en) 2018-03-06
CA2621365C (en) 2012-09-04
US20150157587A1 (en) 2015-06-11
KR20080028374A (ko) 2008-03-31
US12036196B2 (en) 2024-07-16
KR20120094109A (ko) 2012-08-23
JP2008542282A (ja) 2008-11-27
US8980307B2 (en) 2015-03-17
US8394402B2 (en) 2013-03-12
WO2007073398A2 (en) 2007-06-28
EP3081215B9 (en) 2020-08-19
DK1883406T3 (en) 2016-08-15
KR101275660B1 (ko) 2013-06-17
US20090220575A1 (en) 2009-09-03
US20210260005A1 (en) 2021-08-26
US20130030052A1 (en) 2013-01-31
CN106038473A (zh) 2016-10-26
DK3081215T3 (da) 2020-04-27
WO2007073398A3 (en) 2007-09-07
CA2621365A1 (en) 2007-06-28
CN101309688B (zh) 2016-06-22
US9636315B2 (en) 2017-05-02
US10828274B2 (en) 2020-11-10
CN101309688A (zh) 2008-11-19
US20180256528A1 (en) 2018-09-13
EP3081215A1 (en) 2016-10-19
EP1883406B1 (en) 2016-07-06
EP3081215B1 (en) 2020-04-01
EP1883406A2 (en) 2008-02-06
US20160354329A1 (en) 2016-12-08
US8496958B2 (en) 2013-07-30
JP2013224310A (ja) 2013-10-31
US20130142859A1 (en) 2013-06-06
US20140017293A1 (en) 2014-01-16
US8329207B2 (en) 2012-12-11

Similar Documents

Publication Publication Date Title
US12036196B2 (en) Compositions and methods for the sustained release of beta-alanine
EP2201937A1 (en) Formulations comprising vitamin D or derivatives thereof
WO2006035900A1 (ja) コエンザイムｑ１０含有乳化組成物
AU2018100110A4 (en) Ubiquinone And Ubiquinol Compositions, And Methods Relating Thereto
KR20190080875A (ko) 모발 성장 자극을 위한 알파-케토부티레이트, 알파-케토글루타레이트, 및 2-하이드록시부티레이트
KR20210118255A (ko) 고 약물 부하량의 중쇄 트리글리세라이드를 갖는 약학 조성물 및 이와 관련된 방법
RS55057B1 (sr) Kompozicija za tretiranje steriliteta
WO2016135482A1 (en) Compositions comprising co-q10, krill oil and vitamin d
HK1125827A (en) Compositions and methods for the sustained release of beta-alanine
US20250152533A1 (en) Novel Beta-Alanine Compositions and Methods of Use Thereof
CN121985954A (zh) 用于减少与体重减轻相关的肌肉减少和/或抑制肌肉减少症的方法和组合物
CN121489969A (zh) 一种抗衰老的组合物
KR20230136513A (ko) 비타민 c의 안정한 서방성 제형 및 이의 제조 방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20071221

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20080227

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090304

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110314

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120307

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110314

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20120607

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20120307

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20120806

Appeal identifier: 2012101005504

Request date: 20120607

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20120709

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20120709

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20120607

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20110914

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20090304

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20120806

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20120719

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20121004

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20121005

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20150827

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20150827

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20160923

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20160923

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20170926

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20170926

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20180921

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20180921

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20190924

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20190924

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20200924

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20230921

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee